The board of ODI Pharma AB (“ODI” or the “Company”) has today appointed Jan-Mark Edewaard as the new CEO of ODI as of January 1, 2025. Current CEO, Derek Simmross, will remain in his role until January 1, 2025.
“I’m grateful for the opportunity to lead ODI Pharma at such a pivotal time”, said Jan-Mark. “With a strong team and established partnerships, I am focused on ensuring we meet our strategic objectives and continue to deliver quality products to our clients and patients. I look forward to working with the Board and our stakeholders as we build on the company’s progress and prepare for the opportunities and challenges ahead,” comment from Jan-Mark Edewaard.
Starting January 1, 2025, Jan-Mark Edewaard will succeed Derek Simmross as CEO of ODI. Mr. Edewaard holds a Bachelor’s degree in Management, Economics, and Law. With over 25 years of experience from various roles, Jan-Mark began his career in various finance roles and later served as an internal auditor for two large international corporations. In 2009, he assumed responsibility for Finance and Accounting at a Dutch ship-owning company. Two years later, he transitioned to an affiliated company specializing in chemical tanker shipping, where he was appointed CFO. In close collaboration with the CEO, Mr. Edewaard played a pivotal role in the company’s development. He served as CFO until 2019 and has held the position of General Manager for the past five years.
As CEO of ODI, Jan-Mark will be responsible for leading ODI’s efforts to become a competitive provider of medical cannabis in Europe. Under his leadership, ODI Pharma aims to continue to offer high-quality products, supported by a robust European network and strategic partnerships to meet increasing demand. The Company is focused on advancing its understanding of medical applications and bringing innovative solutions to patients in need.
“We are grateful to Derek for his dedication and leadership during the last years, which has laid a foundation for ODI Pharma’s growth. As we look to the future, we are excited to welcome Jan-Mark as CEO. His experience and vision will be invaluable as we continue our journey to expand and strengthen our position in the medical cannabis market,” comments Volker Wiederrich, Chairman of ODI.
For more information on ODI Pharma, please contact:
Volker Wiederrich, Chairman, ODI Pharma AB
E-mail: info@odipharma.com
This information is information that ODI Pharma is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above on November 12, 2024.
ODI Pharma AB
ODI Pharma, based on its European network, subsidiaries and affiliates, is a producer and representative of finished pharmaceutical cannabis products with a focus on distribution to the medical cannabis market in Europe through its subsidiary ODI Pharma Polska Sp. z o.o. ODI Pharma intends to provide a high-quality product at a competitive price compared to competitors in Poland, thereby becoming the number one provider of medical cannabis in Poland. ODI Pharma also strives to be on the forefront of understanding the medical applications of the product as well as introducing new, innovative products to the European patients in need. The Company will continue to team up with the most knowledgeable and best renown partners in the industry to achieve its goals.